Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ihle

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|February 7, 2007
Dynamic correlations in stochastic rotation dynamicsE Tüzel, T Ihle, D M Kroll
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|October 4, 2003
Transport coefficients for stochastic rotation dynamics in three dimensionsE Tüzel, M Strauss, T Ihle, et al.
Cell Cycle (Georgetown, Tex.)|January 24, 2009
Inhibiting PI-3-K for glioma therapyGarth Powis, Nathan T Ihle, W K Alfred Yung
BMC Genomics|June 15, 2016
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicineZhou Zhu, Nathan T Ihle, Paul A Rejto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Stability of phosphoprotein as a biological marker of tumor signalingAmanda F Baker, Tomislav Dragovich, Nathan T Ihle, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2006
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalingRyan Williams, Amanda F Baker, Nathan T Ihle, et al.
Molecular Cancer Therapeutics|January 14, 2009
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activityNathan T Ihle, Robert Lemos, David Schwartz, et al.
Cancer Research|January 2, 2009
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceNathan T Ihle, Robert Lemos, Peter Wipf, et al.
Molecular Cancer Therapeutics|September 20, 2005
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsNathan T Ihle, Gillian Paine-Murrieta, Margareta I Berggren, et al.
Molecular Cancer Therapeutics|July 15, 2004
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signalingNathan T Ihle, Ryan Williams, Sherry Chow, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|February 7, 2007
Dynamic correlations in stochastic rotation dynamicsE Tüzel, T Ihle, D M Kroll
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|October 4, 2003
Transport coefficients for stochastic rotation dynamics in three dimensionsE Tüzel, M Strauss, T Ihle, et al.
Cell Cycle (Georgetown, Tex.)|January 24, 2009
Inhibiting PI-3-K for glioma therapyGarth Powis, Nathan T Ihle, W K Alfred Yung
BMC Genomics|June 15, 2016
Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicineZhou Zhu, Nathan T Ihle, Paul A Rejto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Stability of phosphoprotein as a biological marker of tumor signalingAmanda F Baker, Tomislav Dragovich, Nathan T Ihle, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2006
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalingRyan Williams, Amanda F Baker, Nathan T Ihle, et al.
Molecular Cancer Therapeutics|January 14, 2009
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activityNathan T Ihle, Robert Lemos, David Schwartz, et al.
Cancer Research|January 2, 2009
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceNathan T Ihle, Robert Lemos, Peter Wipf, et al.
Molecular Cancer Therapeutics|September 20, 2005
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsNathan T Ihle, Gillian Paine-Murrieta, Margareta I Berggren, et al.
Molecular Cancer Therapeutics|July 15, 2004
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signalingNathan T Ihle, Ryan Williams, Sherry Chow, et al.
Pageof 3